SCHEMBL103584

SCHEMBL103584

CC=Cc1cc(C(=O)OC)ccc1N1CCCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.47
MEN1 O00255 4/20 0.47
NPC1 O15118 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
KDM4E B2RXH2 2/20 0.46
RAB9A P51151 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
NR1H2 P55055 1/20 0.43
CKS1B P61024 1/20 0.41
SKP1 P63208 1/20 0.41
SKP2 Q13309 1/20 0.41
MAPT P10636 4/20 0.41
ALDH1A1 P00352 3/20 0.41
HPGD P15428 2/20 0.41
ABL1 P00519 1/20 0.41
RIN1 Q13671 1/20 0.41
LMNA P02545 1/20 0.41
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
SLC2A1 P11166 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL103583 1.00 KMT2A (0.47) KMT2AMEN1NPC1SMN1; SMN2KDM4E
SCHEMBL103065 0.96 NR1H2 (0.46) KMT2AMEN1NPC1SMN1; SMN2KDM4E
SCHEMBL102189 0.90 KMT2A (0.48) KMT2AMEN1SMN1; SMN2KDM4ECKS1B
SCHEMBL102190 0.90 KMT2A (0.48) KMT2AMEN1SMN1; SMN2KDM4ECKS1B
SCHEMBL104415 0.88 MEN1 (0.43) KMT2AMEN1CKS1BSKP1SKP2
SCHEMBL106647 0.85 GPR119 (0.44) KMT2AMEN1SMN1; SMN2KDM4ENPSR1
SCHEMBL106646 0.85 GPR119 (0.44) KMT2AMEN1SMN1; SMN2KDM4ENPSR1
SCHEMBL1482043 0.84 KMT2A (0.57) KMT2AMEN1NPC1SMN1; SMN2KDM4E
SCHEMBL103728 0.83 SMARCA2 (0.46) NPC1KDM4ERAB9ANR1H2MAPT
SCHEMBL106277 0.83 KMT2A (0.50) KMT2AMEN1NPC1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2426113-B1 CARBINOL COMPOUND HAVING HETEROCYCLIC LINKER KOWA CO (JP) 2013-11-06 EP disclosed
US-8551985-B2 Carbinol derivatives having heterocyclic linker KOWA COMPANY, LTD. (JP) 2013-10-08 US disclosed
EP-2426113-A1 CARBINOL COMPOUND HAVING HETEROCYCLIC LINKER Kowa Company, Ltd. (JP) 2012-03-07 EP disclosed
US-20100280013-A1 CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER KOWA COMPANY, LTD. (JP) 2010-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280013-A1 CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER NR1H2, NR1H3, CCR2 KMT2A 2327/4885MEN1 3479/4885NPC1 163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.